[Role of ketanserin in the treatment of primary hyperaldosteronism].
Ketanserin (Ket), a 5HT-2 serotoninergic receptor antagonist, is currently used as an antihypertensive agent. In our previous studies, both in vitro and in vivo when administered as bolus i.v. in subjects with primary aldosteronism (IAP), Ket exhibited an inhibitory action on aldosterone secretion. Therefore in the present study we investigated, in IAP patients, the effects of chronic treatment with Ket on blood pressure and mineralocorticoid secretion. Ket was administered at increased doses of 20 and 40 mg twice daily per os for 30 days and the following parameters were evaluated: blood pressure, heart rate, ur. aldosterone, pl. aldosterone both basal and after ACTH and angiotensin II (AII) stimulation, PRA, and atrial natriuretic factor (ANF). Our study demonstrated that Ket is a powerful blood pressure lowering agent with no relevant side effects and no variations of heart rate. Ur and pl aldosterone levels did not change during therapy; correspondingly, Ket did not modify ACTH or AII-induced stimulation. ANF levels, basally elevated in this syndrome, increased during Ket treatment. This new and interesting aspect deserves further evaluation. In conclusion Ket showed an effective antihypertensive effect in this syndrome, even if steroidogenesis inhibition does not seem to be a relevant component of its antihypertensive effect.